Silence Therapeutics plc

Silence Therapeutics plc (SLNCF) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days, suggesting operational stability in the near term. However, low signal in our recent window does not mean low risk—the biotech sector faces structural pressures around financing, share dilution, and clinical-stage burn rates that require deeper analysis. The full $49 Report extends the lookback to 12 months, calculates a dilution risk score based on capital raises and warrant/option loads, contextualizes any 8-K activity, and surfaces AI-detected risk signals missed by surface-level screening. The full $49 Report adds quantified dilution exposure, 12-month event history, financing runway analysis, and algorithmic risk scoring to support conviction on this clinical-stage RNA therapeutics play.